Abstract: A method includes obtaining a set of ranging values between a rangefinder and at least two posts in a battery product, where the set of ranging values is obtained by the rangefinder through ranging of the at least two posts along a first direction parallel to an optical axis of a laser galvanometer after the rangefinder is calibrated based on a first position in the first direction that is a position of a focal point of the laser galvanometer in the first direction, and the rangefinder being at a fixed distance from the laser galvanometer in the first direction; determining a first offset of a welding surface of the battery product relative to the focal point 10 based on the set of ranging values; and determining a first position adjustment amount for the laser galvanometer in the first direction based on the first offset and a first defocus amount.

Abstract: A welding deviation detection device includes a pre-welding addressing mechanism that can determine relative position relations between location holes and poles in a battery, and send the relative position relations to a welding mechanism and a post-welding detection mechanism; the welding mechanism can detect first positions of the location holes, and determine first positions of the plurality of poles based on the first positions of the location holes and the relative position relation, so that the welding mechanism can accurately weld a bus assembly to the plurality of poles based on the first positions of the plurality of poles to form a plurality of welds; and a post-welding detection mechanism that can detect second positions of the location holes and positions of the welds, and detect welding deviation situations of the bus assembly and the poles based on the second positions of the location holes.

Abstract: Provided herein are a crystal form of an isobutyrate nucleoside compound, and a preparation method. The crystal form is III; the X-ray powder diffraction pattern thereof has characteristic peaks at diffraction angles, 2?, 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2° and 28.66±0.2°. The crystal form III has good physical and chemical stability. The preparation method for the crystal form is simple to operate and high in repeatability.

Abstract: The present invention provides a crystalline form of a nucleoside compound. The crystalline form is ATV014 crystalline form I, which has good solubility and thermal stability, and better bioavailability and dissolution profile in specific formulations. The good permeability and thermal stability of the crystalline form make it suitable for use in specific pharmaceutical formulations.

Abstract: The present invention provides novel crystalline forms of a nucleoside compound and salts thereof, which belongs to the technical field of medicines. The nucleoside compound is compound ATV014. The present invention focuses on investigating whether compound ATV014 has multiple solid forms. Surprisingly, it is discovered that compound ATV014 exists in a variety of stable solid forms, comprising: ATV-014 free base crystalline form I, ATV-014 hydrochloride crystalline form I, ATV-014 hydrochloride crystalline form II, ATV-014 hydrochloride crystalline form III, ATV-014 hydrochloride crystalline form IV, ATV-014 hydrobromide crystalline form I, and ATV-014 p-toluenesulfonate crystalline form I.

Abstract: Itraconazole, a widely used antifungal drug, has been found to possess potent anti-angiogenic and anti-hedgehog activities, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolic enzyme CYP3A4 which causes drug-drug interactions. In an effort to eliminate the CYP3A4 inhibition of itraconazole while retaining its anti-angiogenic activity, we synthesized a series of itraconazole derivatives. The newly synthesized analogs of itraconazole were evaluated for their cytotoxicity against human umbilical vein endothelial cells (HUVEC) and their inhibitory activity against CYP3A4 enzyme.

Abstract: An end cover assembly includes: an end cover provided with an electrode lead-out hole; an electrode terminal including a terminal plate located on a side of the end cover and covering the electrode lead-out hole, with an outer peripheral surface protruding from an inner wall of the electrode lead-out hole; a sealing member at least partially disposed between the electrode terminal and the end cover; a fixing member configured to be connected to the end cover and surround the terminal plate so as to fix the electrode terminal onto the end cover, and including a flange extending in a direction approaching an axis of the electrode lead-out hole and located on a side of the terminal plate farther away from the end cover; and a heat-resistant part, at least a portion thereof is located between the flange and the electrode terminal in an axial direction of the electrode lead-out hole.

Abstract: Provided are methods for treating coronavirus infections by administering modified nucleosides, ester and amino acid ester prodrugs of nucleoside, their pharmaceutically acceptable salts, and drug combination thereof, of Formula (I). The compounds, combination, and methods provided are particularly useful for preventing, mitigating, or treating coronavirus infections or cytopathic effects resulting from the replication or reproduction of coronaviruses and their variants, including SARS-CoV-2.

Abstract: Itraconazole, a widely used antifungal drug, has been found to possess potent anti-angiogenic and anti-hedgehog activities, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolic enzyme CYP3A4 which causes drug-drug interactions. In an effort to eliminate the CYP3A4 inhibition of itraconazole while retaining its anti-angiogenic activity, we synthesized a series of itraconazole derivatives. The newly synthesized analogs of itraconazole were evaluated for their cytotoxicity against human umbilical vein endothelial cells (HUVEC) and their inhibitory activity against CYP3A4 enzyme.

Abstract: A welding deviation detection device includes a pre-welding addressing mechanism that can determine relative position relations between location holes and poles in a battery, and send the relative position relations to a welding mechanism and a post-welding detection mechanism; the welding mechanism can detect first positions of the location holes, and determine first positions of the plurality of poles based on the first positions of the location holes and the relative position relation, so that the welding mechanism can accurately weld a bus assembly to the plurality of poles based on the first positions of the plurality of poles to form a plurality of welds; and a post-welding detection mechanism that can detect second positions of the location holes and positions of the welds, and detect welding deviation situations of the bus assembly and the poles based on the second positions of the location holes.

Abstract: A welding apparatus includes a body portion, a welding part disposed on the body portion and configured to weld welding points on a to-be-welded object, and a distance measuring part disposed on the body portion and located on a side of the body portion that faces the welding part. The distance measuring part is configured to measure defocus amounts from the welding points on the to-be-welded object to the welding part. The welding part and the distance measuring part are aligned to different ones of the welding points at a same time, so that the welding part and the distance measuring part simultaneously perform welding and distance measurement on the different ones of the welding points.

Abstract: Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

Abstract: A power conversion system is provided. The power conversion system includes N power conversion circuits. Each power conversion circuit includes an input, an output, two switching power conversion units and at least one resonant capacitor. The input and output are configured to receive an input voltage and output an output voltage respectively. Each switching power conversion unit includes a plurality of switches and a winding. The plurality of switches operates periodically according to a switching period. A dotted terminal of one winding is electrically coupled to an undotted terminal of the other winding. The two windings are magnetically coupled to each other to form a transformer. In one switching period, the resonant capacitor stores an energy or outputs the stored energy as the corresponding switch is turned on or off. A resonance is generated between the resonant capacitor and inductor with a resonant frequency and a resonant period.

Abstract: Itraconazole, a widely used antifungal drug, has been found to possess potent anti-angiogenic and anti-hedgehog activities, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolic enzyme CYP3A4 which causes drug-drug interactions. In an effort to eliminate the CYP3A4 inhibition of itraconazole while retaining its anti-angiogenic activity, we synthesized a series of itraconazole derivatives. The newly synthesized analogs of itraconazole were evaluated for their cytotoxicity against human umbilical vein endothelial cells (HUVEC) and their inhibitory activity against CYP3A4 enzyme.

Abstract: Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

Abstract: A power conversion system is provided. The power conversion system includes N power conversion circuits. Each power conversion circuit includes an input, an output, two switching power conversion units and at least one resonant capacitor. The input and output are configured to receive an input voltage and output an output voltage respectively. Each switching power conversion unit includes a plurality of switches and a winding. The plurality of switches operates periodically according to a switching period. A dotted terminal of one winding is electrically coupled to an undotted terminal of the other winding. The two windings are magnetically coupled to each other to form a transformer. In one switching period, the resonant capacitor stores an energy or outputs the stored energy as the corresponding switch is turned on or off. A resonance is generated between the resonant capacitor and inductor with a resonant frequency and a resonant period.

Abstract: Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

Abstract: The present disclosure discloses a method for positioning an object in a positioning device and the positioning device thereof. The method comprises: transmitting a beam according to a preset mode; receiving a feedback signal sent from an object, wherein the feedback signal is a signal sent by an electronic tag on the object after receiving the beam, and the feedback signal correlates to an intensity of the beam when the electronic tag receives the beam; and determining a position of the object relative to the positioning device according to the feedback signal. Accordingly, the problem of cumbersome operation and poor reliability of manually recording storing locations of objects on a logbook by a user can be solved, and the effect of improving the convenience for positioning object can be achieved.

Abstract: A radio frequency signal transceiver includes: a transmission circuit configured to perform power amplification on an input first analog signal, wirelessly transmit the first analog signal after power amplification, and output the first analog signal after power amplification to a pre-distortion circuit; the pre-distortion circuit configured to convert the first analog signal after power amplification into a second analog signal and output the second analog signal, where the second analog signal is used to feedback distortion of the first analog signal to compensate the first analog signal in advance according to the distortion; and a receiving circuit configured to wirelessly receive a third analog signal, and process and output the third analog signal. The radio frequency signal transceiver can improve efficiency in receiving and transmitting a radio frequency signal, reduce a cost of a base station system, and reduce a difficulty in implementing the base station system.